Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access

[PR Newswire] – TARRYTOWN, N.Y. and BRIDGEWATER, N.J, Dec. 11, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that UnitedHealth Group will provide preferred access to Praluent® (alirocumab) Injection through . . . → Read More: Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access Similar Articles: Company Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Sanofi and Regeneron Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015 Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015 Company Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia